AMEX · Financial Statements

Apimeds Pharmaceuticals US, Inc. (APUS) Revenue, Earnings & Financial Statements

$1.95 AMEX: APUS Market Cap $2.94M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Apimeds Pharmaceuticals US, Inc. most recently reported annual revenue of $0, a net loss of $6.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Apimeds Pharmaceuticals US, Inc.: net profit was positive in 0 of 5 reported years; the most recent year shows a net loss of $6.0M.

Income Statement — 5 Years (USD millions)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Expenses$1.0M$1.0M$1.0M$1.0M$12.0M
Operating Profit−$1.0M−$1.0M−$1.0M−$1.0M−$12.0M
Other Income$0$0$0$0$6.0M
Interest$0$0$0$0$0
Depreciation$0$0$0$0$0
Profit Before Tax−$1.0M−$1.0M−$1.0M−$1.0M−$6.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%
Net Profit−$1.0M−$1.0M−$1.0M−$1.0M−$6.0M
EPS−$8.08−$5.27−$6.13−$11.00−$5.50

Quarterly Results — Last 12 Quarters (USD millions)

4 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$3.0M
Operating Expenses$1.0M$0$0$0$0$0$3.0M$2.0M$7.0M$4.0M$6.0M$1.0M
Operating Profit−$1.0M$0$0$0$0$0−$3.0M−$2.0M−$7.0M−$4.0M−$6.0M$2.0M
Operating Margin———————————70.0%
Interest$0$0$0$0$0$0$0$0$0$1.0M$3.0M$1.0M
Profit Before Tax−$1.0M$0$0$0$0$0−$3.0M−$2.0M−$1.0M−$35.0M−$20.0M$34.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$1.0M$0$0$0$0$0−$3.0M−$2.0M−$1.0M−$35.0M−$20.0M$34.0M
EPS−$4.47−$2.34−$3.54−$2.62−$2.46−$3.48−$26.00−$14.00−$0.92−$22.60−$11.77$5.93

Over the 5 years reported for Apimeds Pharmaceuticals US, Inc., cash stood at $2.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.27 times.

Balance Sheet — 5 Years (USD millions)

Metric20212022202320242025
Total Assets$0$0$0$0$164.0M
Current Assets$0$0$0$0$14.0M
Cash$0$0$0$0$2.0M
Inventory$0$0$0$0$0
Receivables$0$0$0$0$0
Fixed Assets$0$0$0$0$0
Capital Work in Progress$0$0$0$0$0
Investments$0$0$0$0$152.0M
Other Assets$0$0$0$0$0
Total Liabilities$0$1.0M$0$1.0M$11.0M
Current Liabilities$0$0$0$1.0M$11.0M
Borrowings$0$1.0M$0$1.0M$8.0M
Other Liabilities$0$0$0$1.0M$3.0M
Equity$0$0$0$0$0
Reserves$0−$1.0M$0−$1.0M$153.0M

For Apimeds Pharmaceuticals US, Inc., operating cash flow was positive in 0 of 5 reported years; free cash flow in the latest year was negative at $9.0M; free cash flow was positive in 0 of 5 years.

Cash Flow Statement — 5 Years (USD millions)

Metric20212022202320242025
Operating Cash Flow−$1.0M$0−$1.0M−$1.0M−$9.0M
Investing Cash Flow$0$0$0$0−$10.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$0$0$0$0$10.0M
Free Cash Flow−$1.0M$0−$1.0M−$1.0M−$9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.25
FCF Yield-383.37%
Quick Ratio0.83
Interest Coverage-4.79
Return 1Y-93.64%
Return 3Y—
Return 5Y—

Apimeds Pharmaceuticals US, Inc. (APUS) financials — frequently asked questions

What is Apimeds Pharmaceuticals US, Inc.'s annual revenue?

Apimeds Pharmaceuticals US, Inc. (APUS) reported annual revenue of $0 in its most recent fiscal year.

What is Apimeds Pharmaceuticals US, Inc.'s net profit?

Apimeds Pharmaceuticals US, Inc. (APUS) reported a net loss of $6.0M in its most recent fiscal year.

What is APUS EV/EBITDA?

Apimeds Pharmaceuticals US, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.25. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
APUS Overview APUS Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.